These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 22972611)

  • 61. Dual BRD4 and AURKA Inhibition Is Synergistic against MYCN-Amplified and Nonamplified Neuroblastoma.
    Felgenhauer J; Tomino L; Selich-Anderson J; Bopp E; Shah N
    Neoplasia; 2018 Oct; 20(10):965-974. PubMed ID: 30153557
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Anticancer activity of the Aurora A kinase inhibitor MK-5108 in non-small-cell lung cancer (NSCLC) in vitro as monotherapy and in combination with chemotherapies.
    Chinn DC; Holland WS; Mack PC
    J Cancer Res Clin Oncol; 2014 Jul; 140(7):1137-49. PubMed ID: 24756365
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Development of an intravaginal ring for the topical delivery of Aurora kinase A inhibitor, MLN8237.
    Tayyar Y; Shiels R; Bulmer AC; Lam AK; Clarke D; Idris A; McMillan NA
    PLoS One; 2019; 14(11):e0225774. PubMed ID: 31774882
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Synthetic Lethality Interaction Between Aurora Kinases and CHEK1 Inhibitors in Ovarian Cancer.
    Alcaraz-Sanabria A; Nieto-Jiménez C; Corrales-Sánchez V; Serrano-Oviedo L; Andrés-Pretel F; Montero JC; Burgos M; Llopis J; Galán-Moya EM; Pandiella A; Ocaña A
    Mol Cancer Ther; 2017 Nov; 16(11):2552-2562. PubMed ID: 28847989
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Safety and activity of alisertib, an investigational aurora kinase A inhibitor, in patients with breast cancer, small-cell lung cancer, non-small-cell lung cancer, head and neck squamous-cell carcinoma, and gastro-oesophageal adenocarcinoma: a five-arm phase 2 study.
    Melichar B; Adenis A; Lockhart AC; Bennouna J; Dees EC; Kayaleh O; Obermannova R; DeMichele A; Zatloukal P; Zhang B; Ullmann CD; Schusterbauer C
    Lancet Oncol; 2015 Apr; 16(4):395-405. PubMed ID: 25728526
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Molecular imaging of aurora kinase A (AURKA) expression: Synthesis and preclinical evaluation of radiolabeled alisertib (MLN8237).
    Goos JACM; Verbeek J; Geldof AA; Hiemstra AC; van de Wiel MA; Adamzek KA; Delis-Van Diemen PM; Stroud SG; Bradley DP; Meijer GA; Hoekstra OS; Fijneman RJA; Windhorst AD
    Nucl Med Biol; 2016 Jan; 43(1):63-72. PubMed ID: 26432753
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Relative bioavailability of a prototype oral solution of the Aurora A kinase inhibitor alisertib (MLN8237) in patients with advanced solid tumors.
    Falchook GS; Venkatakrishnan K; Sarantopoulos J; Kurzrock R; Mita AC; Fu S; Mita MM; Zhou X; Jung JA; Ullmann CD; Milch C; Rosen LS
    Int J Clin Pharmacol Ther; 2015 Jul; 53(7):563-72. PubMed ID: 26073352
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Inhibition of Aurora A Kinase in Combination with Chemotherapy Induces Synthetic Lethality and Overcomes Chemoresistance in Myc-Overexpressing Lymphoma.
    Park SI; Lin CP; Ren N; Angus SP; Dittmer DP; Foote M; Parton T; Bhatt AP; Fedoriw YD; Roth DP; Cann ML; Johnson GL; Damania B
    Target Oncol; 2019 Oct; 14(5):563-575. PubMed ID: 31429028
    [TBL] [Abstract][Full Text] [Related]  

  • 69. BPR1K653, a novel Aurora kinase inhibitor, exhibits potent anti-proliferative activity in MDR1 (P-gp170)-mediated multidrug-resistant cancer cells.
    Cheung CH; Lin WH; Hsu JT; Hour TC; Yeh TK; Ko S; Lien TW; Coumar MS; Liu JF; Lai WY; Shiao HY; Lee TR; Hsieh HP; Chang JY
    PLoS One; 2011; 6(8):e23485. PubMed ID: 21887256
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Inhibition of Aurora A and Aurora B Is Required for the Sensitivity of HPV-Driven Cervical Cancers to Aurora Kinase Inhibitors.
    Martin D; Fallaha S; Proctor M; Stevenson A; Perrin L; McMillan N; Gabrielli B
    Mol Cancer Ther; 2017 Sep; 16(9):1934-1941. PubMed ID: 28522591
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Alisertib: a review of pharmacokinetics, efficacy and toxicity in patients with hematologic malignancies and solid tumors.
    Liewer S; Huddleston A
    Expert Opin Investig Drugs; 2018 Jan; 27(1):105-112. PubMed ID: 29260599
    [TBL] [Abstract][Full Text] [Related]  

  • 72. A Phase II Study of Alisertib in Children with Recurrent/Refractory Solid Tumors or Leukemia: Children's Oncology Group Phase I and Pilot Consortium (ADVL0921).
    Mossé YP; Fox E; Teachey DT; Reid JM; Safgren SL; Carol H; Lock RB; Houghton PJ; Smith MA; Hall D; Barkauskas DA; Krailo M; Voss SD; Berg SL; Blaney SM; Weigel BJ
    Clin Cancer Res; 2019 Jun; 25(11):3229-3238. PubMed ID: 30777875
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Aurora kinases are a novel therapeutic target for HPV-positive head and neck cancers.
    Shaikh MH; Idris A; Johnson NW; Fallaha S; Clarke DTW; Martin D; Morgan IM; Gabrielli B; McMillan NAJ
    Oral Oncol; 2018 Nov; 86():105-112. PubMed ID: 30409290
    [TBL] [Abstract][Full Text] [Related]  

  • 74. AURKA regulates JAK2-STAT3 activity in human gastric and esophageal cancers.
    Katsha A; Arras J; Soutto M; Belkhiri A; El-Rifai W
    Mol Oncol; 2014 Dec; 8(8):1419-28. PubMed ID: 24953013
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial.
    DuBois SG; Marachelian A; Fox E; Kudgus RA; Reid JM; Groshen S; Malvar J; Bagatell R; Wagner L; Maris JM; Hawkins R; Courtier J; Lai H; Goodarzian F; Shimada H; Czarnecki S; Tsao-Wei D; Matthay KK; Mosse YP
    J Clin Oncol; 2016 Apr; 34(12):1368-75. PubMed ID: 26884555
    [TBL] [Abstract][Full Text] [Related]  

  • 76. SCH 1473759, a novel Aurora inhibitor, demonstrates enhanced anti-tumor activity in combination with taxanes and KSP inhibitors.
    Basso AD; Liu M; Gray K; Tevar S; Lee S; Liang L; Ponery A; Smith EB; Monsma FJ; Yu T; Zhang Y; Kerekes AD; Esposite S; Xiao Y; Tagat JR; Hicklin DJ; Kirschmeier P
    Cancer Chemother Pharmacol; 2011 Oct; 68(4):923-33. PubMed ID: 21298383
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.
    Mohan P; Castellsague J; Jiang J; Allen K; Chen H; Nemirovsky O; Spyra M; Hu K; Kluwe L; Pujana MA; Villanueva A; Mautner VF; Keats JJ; Dunn SE; Lazaro C; Maxwell CA
    Oncotarget; 2013 Jan; 4(1):80-93. PubMed ID: 23328114
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Phase I study of the aurora A kinase inhibitor alisertib with induction chemotherapy in patients with acute myeloid leukemia.
    Fathi AT; Wander SA; Blonquist TM; Brunner AM; Amrein PC; Supko J; Hermance NM; Manning AL; Sadrzadeh H; Ballen KK; Attar EC; Graubert TA; Hobbs G; Joseph C; Perry AM; Burke M; Silver R; Foster J; Bergeron M; Ramos AY; Som TT; Fishman KM; McGregor KL; Connolly C; Neuberg DS; Chen YB
    Haematologica; 2017 Apr; 102(4):719-727. PubMed ID: 28034990
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Effect of Food on the Pharmacokinetics of the Investigational Aurora A Kinase Inhibitor Alisertib (MLN8237) in Patients with Advanced Solid Tumors.
    Falchook GS; Zhou X; Venkatakrishnan K; Kurzrock R; Mahalingam D; Goldman JW; Jung J; Ullmann CD; Milch C; Rosen LS; Sarantopoulos J
    Drugs R D; 2016 Mar; 16(1):45-52. PubMed ID: 26689566
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Combination of Eribulin and Aurora A Inhibitor MLN8237 Prevents Metastatic Colonization and Induces Cytotoxic Autophagy in Breast Cancer.
    Kozyreva VK; Kiseleva AA; Ice RJ; Jones BC; Loskutov YV; Matalkah F; Smolkin MB; Marinak K; Livengood RH; Salkeni MA; Wen S; Hazard HW; Layne GP; Walsh CM; Cantrell PS; Kilby GW; Mahavadi S; Shah N; Pugacheva EN
    Mol Cancer Ther; 2016 Aug; 15(8):1809-22. PubMed ID: 27235164
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.